Readystate Asset Management LP Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Readystate Asset Management LP lessened its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 96.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,603 shares of the company’s stock after selling 109,220 shares during the quarter. Readystate Asset Management LP’s holdings in Keros Therapeutics were worth $267,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP acquired a new position in Keros Therapeutics during the third quarter worth about $213,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 4.7 %

KROS opened at $64.61 on Friday. Keros Therapeutics, Inc. has a 1 year low of $27.31 and a 1 year high of $73.00. The stock has a fifty day moving average price of $60.05 and a 200 day moving average price of $52.56. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -12.40 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.33) EPS. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on KROS shares. Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. Bank of America reduced their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Finally, Guggenheim reaffirmed a “buy” rating and set a $102.00 price target (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $89.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.